保險狗,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
There is nonetheless overlap in the genetic features associated with higher-grade diffuse gliomas. For example, IDH-wildtype glioblastomas and the transition from lower- to higher-grade IDH-mutant gliomas are associated with a variety of generally common molecular alterations, including cell cycle checkpoint inactivation, tumor suppressor gene inactivation, and angiogenesis. Early molecular alterations, including IDH1/2 mutations, tend to be retained at progression, and a subset of tumors treated with alkylating chemotherapy develop a hypermutation phenotype
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
There is nonetheless overlap in the genetic features associated with higher-grade diffuse gliomas. For example, IDH-wildtype glioblastomas and the transition from lower- to higher-grade IDH-mutant gliomas are associated with a variety of generally common molecular alterations, including cell cycle checkpoint inactivation, tumor suppressor gene inactivation, and angiogenesis. Early molecular alterations, including IDH1/2 mutations, tend to be retained at progression, and a subset of tumors treated with alkylating chemotherapy develop a hypermutation phenotype
說好工程故事2024-05-19 17:20:30
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.
賤種保險狗真係唔識字,唔撚識就查字典啦
Formation of glioblastoma and transition from low-grade to high-grade glioma — In the past, tumors termed "glioblastoma" had been divided into those that arose de novo ("primary") and those that arose in the setting of lower-grade astrocytic gliomas ("secondary"). However, as of the 2021 WHO classification, "glioblastomas" are defined as being IDH-wildtype; the majority of these tumors would have been termed "primary glioblastomas" in the prior literature. By contrast, the IDH-mutant astrocytomas that progress to WHO grade 4 lesions are the tumors that would have been termed "secondary glioblastoma" in the past.